Silkim Pharma

Silkim Pharma Overview

Silkim Pharma has developed a novel, protected platform of drugs for proven treatments of multiple indications. The company's platform is the result of extensive investigation of animal models of human diseases. Members of the platform act as potent anti-inflammatory agents, strong iron-chelating agents, and antibiotic agents. These modes of action jointly assist in treating the causes and/or symptoms of multiple indications.

Latest News

May 24, 2020 · jlm-biocity.org

growth-positive

Silkim Pharma's New Drug Against Coronavirus Receives Response from FDA in Record Time!! - JLM-BioCity

Silkim Pharma has filed a pre-Investigational New Drug (PIND) meeting request with the FDA for its drug candidate CORONZOT in the treatment of COVID-19 patients. The FDA responded positively and provided guidance on the planned clinical study. Silkim Pharma plans to submit an IND application for CORONZOT. The drug addresses the exaggerated immune system reaction caused by the coronavirus. It employs a novel mechanism based on sequestration of labile iron and introduces an ion of gallium or zinc. Silkim Pharma is a pharmaceutical company established in 2017 and is focused on developing drugs for multiple indications.

Investment

Funding

Team Members

2

Employees: 1-10

Web & Social Links

Locations

Ranana, Israel

Photos & Videos

No files yet

Silkim Pharma Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info